Country Club Bank Buys 11,888 Shares of Zimmer Biomet Holdings, Inc. $ZBH

Country Club Bank grew its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 24.7% in the third quarter, according to its most recent filing with the SEC. The fund owned 59,943 shares of the medical equipment provider’s stock after acquiring an additional 11,888 shares during the period. Country Club Bank’s holdings in Zimmer Biomet were worth $5,891,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the company. Cary Street Partners Investment Advisory LLC raised its position in Zimmer Biomet by 83.7% in the second quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock valued at $30,000 after purchasing an additional 149 shares during the last quarter. Headlands Technologies LLC bought a new position in Zimmer Biomet in the 2nd quarter valued at approximately $37,000. CoreFirst Bank & Trust acquired a new stake in Zimmer Biomet during the 2nd quarter worth approximately $38,000. Hilltop National Bank bought a new stake in Zimmer Biomet during the 2nd quarter worth approximately $42,000. Finally, True Wealth Design LLC increased its position in Zimmer Biomet by 875.0% in the 2nd quarter. True Wealth Design LLC now owns 468 shares of the medical equipment provider’s stock valued at $43,000 after acquiring an additional 420 shares during the period. Institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.7%

Shares of ZBH stock opened at $91.53 on Thursday. The company has a market cap of $18.14 billion, a P/E ratio of 22.66, a PEG ratio of 2.39 and a beta of 0.61. Zimmer Biomet Holdings, Inc. has a fifty-two week low of $85.33 and a fifty-two week high of $114.44. The stock has a 50 day simple moving average of $95.21 and a two-hundred day simple moving average of $96.70. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.39 and a current ratio of 2.43.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a net margin of 10.05% and a return on equity of 12.85%. The company had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter last year, the firm posted $1.74 EPS. The company’s quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. Research analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current year.

Zimmer Biomet Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, January 30th. Stockholders of record on Tuesday, December 30th will be issued a dividend of $0.24 per share. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 annualized dividend and a dividend yield of 1.0%. Zimmer Biomet’s dividend payout ratio is currently 23.76%.

Analyst Ratings Changes

Several analysts recently weighed in on ZBH shares. Johnson Rice set a $112.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, November 5th. Barclays reduced their price target on Zimmer Biomet from $112.00 to $105.00 and set an “underweight” rating on the stock in a research report on Wednesday, November 5th. Citigroup lowered their price objective on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research report on Thursday, December 11th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $100.00 target price (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Zimmer Biomet in a report on Wednesday, October 8th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, twelve have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $107.50.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.